<DOC>
	<DOCNO>NCT03106571</DOCNO>
	<brief_summary>This first study pomaglumetad human use methamphetamine . The goal study determine pomaglumetad safe administer methamphetamine . If show safe methamphetamine current study , phase 2 clinical trial pomaglumetad would do begin find pomaglumetad effective treat methamphetamine use disorder .</brief_summary>
	<brief_title>Phase 1 Study Pomaglumetad Methamphetamine</brief_title>
	<detailed_description>The study design randomize , double-blind , placebo-controlled multiple ascending-dose study pomaglumetad 24 non-treatment seek participant methamphetamine use disorder . Three cohort 8 participant ( total N = 24 ) enrol within cohort participant randomly assign 6:2 ratio undergo methamphetamine infusion assessment treatment pomaglumetad ( N = 6 per cohort ) placebo ( N = 2 per cohort ) . Participants cohort 1 receive pomaglumetad 40 mg orally twice daily ( BID ) placebo , cohort 2 receive pomaglumetad 80 mg BID placebo , cohort 3 receive pomaglumetad 160 mg BID placebo . After complete outpatient baseline screening/eligibility assessment , eligible participant admit UCLA Hospital remain hospitalized experimental procedure ( approximately 11 day 10 night ) . A urine drug toxicology screen free illicit substance ( exception THC ) require admission . Upon admission , participant receive sample/test infusion MA 30 mg IV . Participants tolerate test infusion ( serious adverse advent exceed stop criterion ) randomize receive POMA ( 40 mg BID cohort 1 , 80 mg BID cohort 2 , 160 mg BID cohort 3 ) placebo . Following three day MA abstinence POMA/placebo dose achieve study medication steady-state , participant complete MA self-administration session . After two day MA washout , participant serial plasma sample collect 12 hour assess PK POMA . The next day , participant receive 30 mg MA infusion follow serial plasma sample collection follow 48 hour MA PK analysis . Measures cardiovascular response , subjective effect , adverse event assess follow MA infusion self-administration PK session . Upon completion PK sample collection , participant discharge 14-day post-discharge ( ± 7 day ) follow-up outpatient visit complete safety purpose .</detailed_description>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>1. seek treatment MA problem time study ; 2 . Englishspeaking ; 3. age 1855 year inclusive ; 4. meet DSM5 criterion MA use disorder , moderatesevere diagnose via MINI ; 5. selfreported history use MA either via injection smoke provide least one MApositive urine prior admission ; 6. provide urine drug screen negative illicit drug , except THC , day schedule inpatient admission ; 7. report methamphetamine use 10 day past 30 day baseline ; 8. rest heart rate ≤ 100 bpm , systolic blood pressure ≤ 160 mm Hg , diastolic blood pressure ≤ 100 mm Hg prior admission ; 9. baseline EKG demonstrate normal sinus rhythm , QTc ≤ 450 msec men QTc ≤ 460 msec woman , clinically significant arrhythmia ; 10. female ( except female nonchildbearing potential—e.g. , least 1 year postmenopausal surgically sterile ) , pregnant confirm negative pregnancy test lactate willing use medically approve method birth control prevent pregnancy trial 40 day last dose study medication ; 11. male , willing refrain donate sperm study 100 day follow last dose study medication agree partner use medically approve contraceptive method ; 12. medical history physical/neurological examination demonstrate additional clinically significant contraindication study participation , judgment investigator ; 13. able participate schedule evaluation , likely complete schedule test , likely adherent , opinion investigator ; 14. agree post personal medical data information relate study social medium site website trial complete . 1. nonEnglish speaking ; 2. currently probation parole ; 3. current cocaine , opioid , marijuana , alcohol use disorder , moderatesevere ; 4. liver function test ( total bilirubin , ALT , AST , alkaline phosphatase ) ≥ 2 x upper limit normal kidney function test ( creatinine BUN ) ≥ 2 x upper limit normal ; 5. current past history seizure disorder ; 6. history head trauma result neurological sequela ; 7. major psychiatric disorder due substance abuse ( e.g. , schizophrenia , bipolar illness except stable major depressive disorder , generalize anxiety disorder , etc . ) assess MINI ; 8. current neurological disorder ( e.g. , organic brain disease , dementia ) medical condition would make study compliance difficult compromise inform consent ; 9. current ongoing treatment psychotropic medication ( e.g . antidepressant , antipsychotic , antiepileptic , sedative/hypnotics , narcotic analgesic ) ; 10. history suicide attempt ( ) past 6 month active suicidal intention plan ( score 4 5 ) past month assess CSSRS ; 11. evidence clinically significant heart disease hypertension ; 12. evidence untreated unstable serious medical illness include : neuroendocrine , autoimmune , renal , hepatic , active infectious disease include active tuberculosis infection ; 13. HIV infection currently symptomatic , diagnosis AIDS , receive antiretroviral medication ; 14. medical condition make maintain reliable intravenous access impossible ; 15. donate blood plasma within 3 month inpatient admission ; 16. use OAT1 inhibitor ( e.g . probenecid , uricosurics , antiviral , nonsteroidal antiinflammatories , loop diuretic , angiotensin II receptor antagonist , proton pump inhibitor , statin ) CYP2D6 inducer inhibitor within 14 day five halflives , whichever longer , admission ; 17. currently employ UCLA Denovo firstdegree relative UCLA Denovo employee ; 18. circumstance , opinion investigator , would compromise participant safety and/or successful completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase 1 clinical trial</keyword>
</DOC>